ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31

ZEVRA THERAPEUTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$10.16+0.22 (+2.21%)

Close on Oct 19, 2026

Market cap: $623.18M
P/E (TTM): 10.9
Dividend yield: –

ZEVRA THERAPEUTICS, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31
Revenue	106	24	27	10	29	13	13	0	–	–	0	0	0
Cost of Revenue	16	7.42	2.17	0.22	2.06	–	10	0	–	–	–	–	–
Gross Profit	90	16	25	9.94	27	–	2.84	0	–	–	–	–	–
Research & Development	13	42	40	20	10	8.84	19	42	21	20	14	12	3.37
Selling, General & Admin	78	55	34	15	–	–	–	–	–	–	–	–	–
General & Administrative	–	–	–	15	8.70	7.92	11	13	13	14	8.88	4.53	1.35
Operating Expenses	–	–	–	–	–	–	–	56	33	37	23	16	4.72
Total Costs & Expenses	90	97	74	53	21	19	33	56	–	–	–	–	–
Operating Income	-63	-87	-50	-43	7.73	-5.61	-20	-56	-33	-37	-23	-16	-4.72
Interest Expense	7.98	7.35	1.50	0.34	0.23	4.79	4.86	5.47	5.78	5.51	2.67	1.61	0.16
Other Non-Operating Income	150	-3.14	3.56	16	-16	-7.19	-4.21	-0.69	-10	21	-32	-8.03	-0.53
Asset Impairment Charges	0	0	0	0	0	0	0	0	0	0	0	0	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	-0.10	-0.09	–	–	–
Pretax Income	87	-90	-46	-27	-8.52	-13	-25	-57	-43	-17	-55	-24	-5.25
Income Tax Expense	3.45	15	0	-0.03	0.03	-0.03	-0.02	-0.13	-0.04	-0.02	0.03	-0.02	-0.02
Net Income	83	-106	-46	-27	-8.56	-13	-25	-56	-43	-17	-55	-24	-5.23
Preferred Dividends	0	0	–	0	54	0	–	–	–	–	–	–	–
Net Income to Common	78	-106	-46	-27	-63	-13	–	–	–	–	–	–	–
EPS (Basic)(per share)	1.40	-2.28	-1.30	-0.78	-2.11	-3.21	-13.23	-50.40	-47.36	-18.08	-118.72	-164.32	-35.20
EPS (Diluted)(per share)	1.35	-2.28	–	–	-2.11	-3.21	-13.23	-50.40	-47.36	-18.08	-118.72	-164.32	-35.20
Shares Outstanding (Basic, Weighted)(shares)	55	46	35	34	30	3.98	1.85	1.12	0.92	0.91	0.46	0.15	0.15
Shares Outstanding (Diluted, Weighted)(shares)	57	46	35	34	30	3.98	1.85	1.12	0.92	0.91	0.46	0.15	0.15
EBITDA	-59	-81	-49	-42	7.99	-5.34	-20	-56	-33	-37	-23	-16	-4.65

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 95.5%
Operating margin: 60.5%
Net margin: 42.8%
Return on equity, FY2025: 85.7%

Financial strength

Current ratio: 5.17
Debt to equity: 0.00
Debt to assets: 0.0%
Cash to current liabilities: 298.8%

Valuation

P/E ratio: 10.9
Price to sales: 4.58
Price to book: 2.86
Dividend yield: –